Peptac Ensures
Rapid relief in GERD.
Significant reduction in gastric ulcer recurrence.
Better Duodenal Ulcer healing as compare to other H2 receptor antagonist.
Cardiovascular safety profile.
Standard dosage.
Safety & Efficacy with Alu-Alu packing.
COMPOSITION:
Each white color tablet contains 150mg, 300mg DC ranitidine.
INDICATIONS: Duodenal ulcer, Benign gastric ulcer hypersecretory conditions such as Zollinger Ellison Syndrome, Reflux oesophagitis, Chronic episodic dyspepsia. Peptac Tablets are also recommended for use in the prevention of duodenal and gastric ulcers.
MECHANISM OF ACTION: Peptac |Ranitidine150mg, 300mg DC) as a specific fast acting histamine H2 Receptor antagonist. It reduces secretions of gastric acid both the volume and the contents of the acid and pepsin secretions. It also gives rapid relief of pain associated with Peptic ulceration usually within one week of treatment. Peptac has long duration of action and provides adequate relief within a single daily dose at bed lime.
DOSAGE & ADMINISTRATION: (a) GASTRIC & DUODENAL ULCER.
One tablet twice daily for 4 weeks or two tablets at bed time for 4 weeks for maintenance treatment and prevention of ¦ecurrence of ulcers, one tablet daily may be taken at bed time, (b)
CHRONIC EPISODIC DYSPEPSIA. One tablet twice daily for upto 6 weeks.
REFLUX OESOPHAGITIS: In mild to moderate conditions one tablet twice daily or two tablets taken at bed time for upto 8 weeks. In severe oesophagitis not responding to standard treatment, two tablets 4 times daily for 8 weeks may be used.
ZOLLINGER ELLISON SYNDROME: In pathological hypersecretory conditions such as Zollinger Ellison Syndrome, the initial dose is one tablet 2-3 times daily may be increased if necessary. Dose af ranitidine upto 6 grams daily have been used.
STRESS ULCER: Generally, in patients of stress Ulcer one tablet twice daily may be given. In patients with danger of developing acid aspiration syndrome during general anaesthesia, a dose of one tablet of Peptac (Ranitidine 150mg, 300mg DC) may be given 2 hours before the induction of anaesthesia.
PRECAUTIONS: GASTRIC NEOPLASM. When starting therapy with Peptac tablets (150mg, 300mg DC) possibility of malignancy should be excluded.
RENAL DYSFUNCTION. Since ranitidine is mainly excreted by the kidney Peptac tablets should be administered with caution in patients with impaired renal function, one tablet daily may be used if creatinine clearance falls to or below 30ml/min.
PREGNANCY AND FEEDING MOTHERS: Ranitidine crosses placental barrier and is excreted into breast milk where concentrations are reported to be higher than those in plasma. Therefore the drug should be avoided | in such patients unless and until it is considered absolutely necessary after evaluating the risk and benefit ratio. However it does not readily cross the blood brain barrier. Regular supervision of 5 patients particularly the elderly with Peptic ulcer or on non-steroidal anti-inflammatory drug is desirable.
CONTRAINDICATIONS: Ranitidine is contra-indicated in patients with known hypersenstivity | to the drug.
SIDE EFFECTS: 1. In very rare cases hepatocellular, hepatoconalicular or mixed with or without jaundice, have beenoccured.
2. Very rarely, leucopenia and Pancytopenia have been I occurred.
3. Sometimes marrow hypoplasia have been reported.
4. Hypersenstivity reactions (e.g. Urticaria, angioneurotic oedema, bronchospasm, hypotension) have been seen very rarely.
5. J Headache.
6. Swelling and / or discomfort of breast.
DRUG INTERACTION:
No drug intractions have been reported. Ranitidine dose not interact with cytochrome P450 linked drug, metabolizing 1 enzyme system. Compounds metabolized by Dirs system which have been used in man have included warfarin. Theophylline, Phenytoin, Diazepam and Propranolol. J Presentation: Peptac 150mg, DS 300mg: Pack of 10's Tablets Alu-Alu pack. Peptac 50mg Injection pack of 10 Ampoules. I
0 comments